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deviation vector ranged from 0.34 mm to 0.82 mm with an 
average of 0.58 mm and a SD of 0.16 mm. Using the new 
method of calibration, the 3D deviation vector between 
the ET X-ray isocenter and the LIS isocenter was on 
average reduced threefold. 
Conclusion  
Using an in-house made software, a new user independent 
method of co-calibrating the X-ray isocenter of the ET 
system with the LIS isocenter was developed. The new 
method reduced the deviation between the two isocenters 
threefold and brought them into alignment within one 
tenth of a millimetre. This may be of clinical relevance in 
radiotherapy operating with small margins and steep dose 
gradients i.e. as used in stereotactic radiotherapy. 
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Purpose or Objective  
Dosimetry Check software (DC) has been under 
commissioning to be used as a patient specific delivery 
quality assurance (DQA) tool in the TomoTherapy machine 
recently installed at our institution. The purpose of this 
work is to present the workflow from pre-treatment 
verification with DC comparing it with the standard film 
dosimetry towards in-vivo patient dosimetry having transit 
dosimetry with a homogeneous phantom as an 
intermediate step. 
Material and Methods  
The retrospective study used MVCT detector sinograms of 
23 randomly selected clinical cases to perform i) pre-
treatment verifications, with the table out of the bore, ii) 
transit dosimetry for DQA verification plans calculated in 
a Cheese Virtual WaterTM phantom and iii) in-vivo 
dosimetry using the sinogram of the first treatment 
fraction for each of the 23 patients. The 3D dose 
distribution in the phantom/patient CT images was 
reconstructed in Dosimetry Check v.4, Release 10 (Math 
Resolutions, LLC) using a Pencil Beam (PB) algorithm. In 
the pre-treatment mode, Gamma passing rate acceptance 
limit was 95% using a 3%/3mm criterion. The results have 
been correlated with the standard film based pre-
treatment verification methodology, using Gafchromic 
EBT3 film with triple channel correction. 
In transit mode, with the Cheese Phantom, two groups 
were identified: one with clinical cases in which the 
longitudinal treatment extension exceeded the phantom 
limits (group I) and another one with cases where the 
whole treated volume was inside the phantom (group II). 
In this mode, a 5%/3mm criterion was used in Gamma 
analysis. The acceptance limit was again 95%. This was 
also the criterion for in-vivo dosimetry in the first fraction 
of each of the 23 patients. 
Results  
There was a good agreement between planned and 
measured doses when using both pre-treatment and 
transit mode. In the pre-treatment approach the mean 
and standard deviation Gamma passing rates were 
98.3±1.2% for 3%/3mm criterion correlating well with the 
results in film. Concerning transit analysis in Cheese 
phantom, 8 out of 23 cases – group I – presented poor 
Gamma passing rates of 93.8±2.2% (1SD) on average for 
5%/3mm. This was caused by partial volume effect at the 
edges of the phantom as the longitudinal treatment 
extension exceeded its limits. Considering the other 15 
cases – group II – the global Gamma passing rates were 
significantly better 99.5±0.7% (1SD), 5%/3mm.  
Using the sinogram from the first fraction delivered to 
each patient, the passing rates were 98.7±1.4% (1SD), on 
average. 
Conclusion  
The presented results indicate that Dosimetry Check 
software using either pre-treatment or transit mode is a 
reliable tool for patient specific DQA in TomoTherapy 
easily integrable in the routine workflow and without 
major time allocation requirements. Further 
investigation needs to be done on DC ability to detect 
discrepancies during the treatment course, namely if it 
will be able to alert for re-planning need. 
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Purpose or Objective  
There is increasing interest in radiotherapy (RT)-based 
organ preservation strategies for early stage rectal 
cancer. However, standard RT for locally advanced rectal 
cancer uses a large pelvic target volume, which may 
represent overtreatment of early cancers with a low risk 
of nodal involvement and could cause significant 
morbidity. Thus the international, multi-centre phase II/III 
STAR-TReC trial, aiming at organ preservation, will use a 
mesorectal-only irradiation approach for early rectal 
cancer. Furthermore, in order to limit normal tissue 
toxicity risk, IMRT or VMAT may be used. We explored the 
advantages in terms of clinical target volume and organ at 
risk (OAR) doses of a mesorectal-only target volume 
compared to a standard target volume for short-course RT, 
and compared VMAT and 3D-conformal radiotherapy (3D-
CRT) for mesorectal-only irradiation. We also aimed at 
establishing optimal planning objectives for mesorectal-
only short-course VMAT. 
Material and Methods  
We conducted a retrospective planning study of 20 
patients with early rectal cancer: 15 men, 5 women; 1 
high, 10 mid, 9 low tumours; 4 T1, 13 T2, 3 T3a; all N0; 13 
treated prone, 7 supine. Standard CTV encompassed the 
mesorectum, obturator lymph nodes, internal iliac nodes 
and pre-sacral nodes cranio-caudally from puborectalis to 
the S2-3 vertebral junction (as per the UK phase III 
Aristotle trial). The mesorectal-only CTV included the 
mesorectum only from 2cm caudal of the tumour up to the 
S2-3 vertebral junction. VMAT plans (6MV FFF, single arc) 
delivering 5x5Gy to the mesorectal PTV were optimized 
using a Monte Carlo-based treatment planning system. 
They were compared to 5x5Gy three-field 3D-CRT plans, 
for standard and mesorectal targets. We considered target 
coverage, plan conformity (CI), and doses to bowel cavity, 
bladder and femoral heads. Metrics were compared using 
the Wilcoxon signed rank test. VMAT optimization 
objectives for OAR were established by determining dose 
metric objectives achievable for ≥90% (bowel cavity) and 
≥95% (bladder and femoral heads) of patients. 
 
 





Mesorectal-only CTVs were median 59% smaller than 
standard CTVs (interquartile range 58-63%, p<0.001). All 
VMAT and 3D-CRT plans had V95%=100% for the CTVs, while 
V95% of the PTV was comparable for VMAT and 3D-CRT plans 
(median 99.4% vs 99.6%). Table 1 summarizes doses to 
OARs and CI. All OAR doses for mesorectal-only irradiation 
were significantly reduced with VMAT compared to 3D-
CRT; p<0.001 for all metrics. Suggested optimization 
objectives for OAR for mesorectal-only VMAT were 
V10Gy<200cm3, V18Gy<120cm3, and V23Gy<90cm3 for bowel 






VMAT provides dosimetric advantages over 3D-CRT for 
mesorectal-only target volumes. The recommended OAR 
optimization objectives allow for clinical implementation 
of IMRT/VMAT with improved OAR sparing compared to 3D-
CRT standard treatment. These objectives will, after 
independent validation, be used in the multi-centre STAR-
TReC trial. 
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Purpose or Objective  
The Imaging and Radiation Oncology Core (IROC) 
Cooperative has been active for the past two years 
supporting the National Cancer Institute’s (NCI) National 
Clinical Trial Network (NCTN), its clinical trials and the 
details of that support are reported in this work. 
 
 
Material and Methods  
There are six QA centers (Houston, Ohio, Philadelphia-RT, 
Philadelphia-DI, Rhode Island, St. Louis) providing an 
integrated radiation therapy (RT) and diagnostic imaging 
(DI) quality control program in support of the NCI’s clinical 
trials. The former cooperative group QA centers brought 
their expertise and infrastructure together when IROC was 
formed in the new NCTN structure. The QA Center’s 
efforts are focused on assuring high quality data for 
clinical trials designed to improve the clinical outcomes 
for cancer patients worldwide. This program is 
administered through five RT and DI core support services: 
site qualification, trial design support/assistance, 
credentialing, pre- and post-case review data 
management, and case review. IROC also provides 
educational efforts to improve the understanding of the 
protocols by participating institutions. IROC monitors over 
2000 participating institutions that include nearly 100 
participating institutions outside of North America. 
Results  
IROC currently provides core support for 172 NCTN trials 
with RT, DI and RT/DI components. Many of these trials 
were legacy trial from the previous cooperative group 
program. IROC monitors nearly 1800 RT photon and 20 
proton institutions. Over 28,000 beams outputs were 
monitored with 8% of the sites requiring repeat audits due 
to beam out of criteria. As part of credentialing, 950 QA 
phantoms have been irradiated, 515 imaging modalities 
evaluated and almost 4000 credentialing letters have been 
issued. In just year 2, 5290 RT and 4934 DI patient datasets 
were received (many using TRIAD) by IROC QA Centers to 
be prepared for review. During the past 2 years, a total of 
6300 RT cases and 19,000 DI image sets were reviewed by 
IROC technical staff.  To date, IROC has published 36 
manuscripts. 
Conclusion  
The QA services provided by IROC are numerous and are 
continually being evaluated for effectiveness, harmonized 
across all NCTN Groups and administered in an efficient 
and timely manner to enhance accurate and per protocol 
trial data submission. These efforts increase each NCTN 
Group’s ability to derive meaningful outcomes from their 
clinical trials. 
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Purpose or Objective  
 Recently, the use of nanoparticles with a high atomic 
number as a new class of radiation sensitizers, to increase 
the tumor dose and sparing normal tissues has become a 
hot topic in radiotherapy treatments. Meanwhile, Bismuth 
and Gadolinium based nanoparticles, can not only be used 
